Medical Imaging

ConcertAI Addresses Medical AI Reimbursement Barrier with TeraRecon DETECT

ConcertAI Addresses Medical AI Reimbursement Barrier with TeraRecon DETECT

New Solution Provides Reimbursable AI Biomarkers and Reduces Clinician Administrative Time While Helping Identify Opportunities to Optimize Reimbursement Potential for Hospitals Through Streamlined AI-first Workflows

ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization, and interoperability solutions, today announced TeraRecon DETECTTM, an AI-powered platform that helps identify opportunities to optimize reimbursement for multiple imaging biomarkers. With TeraRecon DETECTTM, patients get improved screening with more confident diagnoses, clinicians spend more time with their patients than on paperwork, and administrators can streamline operational workflows to ultimately help optimize reimbursement potential.

Despite significant advances in AI medical imaging, reimbursement remains a major barrier to adoption. More than 1,000 FDA-cleared imaging algorithms can help detect diseases but only about one-third of AI-related claims have been reimbursed, according to a study in the Journal of the American College of Radiology. Hospitals and clinics remain cautious about adopting AI at scale, leaving innovation to outpace the financial and administrative infrastructure needed to support it. TeraRecon DETECTTM is purpose-built to close that gap. It integrates healthcare IT systems like EMR, reporting, and advanced imaging visualization to streamline prior authorization and operational processes, automate clinical eligibility approvals, standardize diagnostic reports, and provide real-time financial performance insights.

“We firmly believe that innovation in healthcare and life sciences should always work toward the ultimate goal of improving patient care,” said Eron Kelly, CEO of ConcertAI. “Launching TeraRecon DETECTTM isn’t just about equipping practitioners with the latest AI-empowered imaging capabilities but ensuring they have the clinical, operational and administrative support so that providing these services won’t be a burden to their organization or their patients.”

Empowering Clinicians with Improved Patient Care and Decreased Paperwork Burden

Clinicians require tools that provide early and accurate disease detection for more confident diagnoses without adding complexity to their routine workloads. TeraRecon DETECTTM provides them with the following:

  • Access to multiple AI Imaging Biomarkers: includes a wide range of reimbursable AI-enabled biomarkers for Radiology (such as Liver and Bone Density) and Cardiology (such as Plaque Analysis).
  • Clinical Process Automation: eliminates the need for the reader to determine patient eligibility for the imaging biomarkers and removes them from the burden of extra manual steps, helping to ensure compliance with payer requirements from the start. 
  • AI-integrated reports for better patient care downstream: supports longitudinal case management and integration of AI capabilities into clinical workflows, ensuring patients benefit from streamlined diagnostic processes and standardized reporting.

“As the healthcare system continues to battle financial and operational pressures, AI is a lifeline not only for hospitals’ financial standing but for clinicians who face burnout due to the ever-growing demand for their time,” said Dhiraj Carumbaya, SVP and General Manager of TeraRecon, a ConcertAI company. “We designed TeraRecon DETECTTM to help them focus on what matters most – giving patients the most informed diagnoses and therefore driving up the standard of care.”

Providing Administrators and Executives with Reimbursable Workflows

Imaging Services administrators at hospitals are focused on operational efficiency, cost control, and maintaining a high standard of care. They want to invest in AI solutions that deliver a clear return on investment and improve the hospital’s competitive standing. TeraRecon DETECTTM provides them with the ability to:

  • Drive adoption of reimbursable imaging biomarkers: harness multiple reimbursable AI biomarkers to help improve clinical diagnosis while helping ensure compliance with payer requirements from the start.
  • Improve reimbursement visibility and efficiencies: EMR integrated ordering and eligibility workflow automations, AI driven prompts for business intelligence, and reimbursement analytics help decrease the chances of denials, improve resource allocation, and minimize staff time spent on repetitive administrative work. 
  • Real-time business intelligence: dashboards provide actionable insights into denial rates, reimbursement trends, and operational inefficiencies, enabling smarter, proactive cost management.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

Concert AI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers and medical societies. TeraRecon provides AV, AI-first workflow solutions, and image viewing solutions for medical imaging, including 3D post-processing tools used in radiology, cardiology, neurology and oncology. CancerlinQ® is an initiative of ConcertAI, providing oncology providers with ASCO--aligned automated QOPI and ASCO Certified® quality solutions and SmartlinQ™ analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham and Tokyo. For more information, visit us at concertai.com.

Related posts

SandboxAQ Collaborates with Mayo Clinic on Novel Cardiac Diagnostics

PR Newswire

Vizgen and Hamamatsu Partner to Streamline Spatial Biology Workflows

PR Newswire

Mach7 Technologies showcases advanced informatics innovations at SiiM25

PR Newswire